Cargando…

Marine-Sourced Anti-Cancer and Cancer Pain Control Agents in Clinical and Late Preclinical Development (†)

The marine habitat has produced a significant number of very potent marine-derived agents that have the potential to inhibit the growth of human tumor cells in vitro and, in a number of cases, in both in vivo murine models and in humans. Although many agents have entered clinical trials in cancer, t...

Descripción completa

Detalles Bibliográficos
Autores principales: Newman, David J., Cragg, Gordon M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3917273/
https://www.ncbi.nlm.nih.gov/pubmed/24424355
http://dx.doi.org/10.3390/md12010255
_version_ 1782302822058950656
author Newman, David J.
Cragg, Gordon M.
author_facet Newman, David J.
Cragg, Gordon M.
author_sort Newman, David J.
collection PubMed
description The marine habitat has produced a significant number of very potent marine-derived agents that have the potential to inhibit the growth of human tumor cells in vitro and, in a number of cases, in both in vivo murine models and in humans. Although many agents have entered clinical trials in cancer, to date, only Cytarabine, Yondelis(®) (ET743), Eribulin (a synthetic derivative based on the structure of halichondrin B), and the dolastatin 10 derivative, monomethylauristatin E (MMAE or vedotin) as a warhead, have been approved for use in humans (Adcetris(®)). In this review, we show the compounds derived from marine sources that are currently in clinical trials against cancer. We have included brief discussions of the approved agents, where they are in trials to extend their initial approved activity (a common practice once an agent is approved), and have also included an extensive discussion of the use of auristatin derivatives as warheads, plus an area that has rarely been covered, the use of marine-derived agents to ameliorate the pain from cancers in humans, and to act as an adjuvant in immunological therapies.
format Online
Article
Text
id pubmed-3917273
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-39172732014-02-10 Marine-Sourced Anti-Cancer and Cancer Pain Control Agents in Clinical and Late Preclinical Development (†) Newman, David J. Cragg, Gordon M. Mar Drugs Review The marine habitat has produced a significant number of very potent marine-derived agents that have the potential to inhibit the growth of human tumor cells in vitro and, in a number of cases, in both in vivo murine models and in humans. Although many agents have entered clinical trials in cancer, to date, only Cytarabine, Yondelis(®) (ET743), Eribulin (a synthetic derivative based on the structure of halichondrin B), and the dolastatin 10 derivative, monomethylauristatin E (MMAE or vedotin) as a warhead, have been approved for use in humans (Adcetris(®)). In this review, we show the compounds derived from marine sources that are currently in clinical trials against cancer. We have included brief discussions of the approved agents, where they are in trials to extend their initial approved activity (a common practice once an agent is approved), and have also included an extensive discussion of the use of auristatin derivatives as warheads, plus an area that has rarely been covered, the use of marine-derived agents to ameliorate the pain from cancers in humans, and to act as an adjuvant in immunological therapies. MDPI 2014-01-14 /pmc/articles/PMC3917273/ /pubmed/24424355 http://dx.doi.org/10.3390/md12010255 Text en © 2014 by the authors; licensee MDPI, Basel, Switzerland. http://creativecommons.org/licenses/by/3.0/ This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/3.0/).
spellingShingle Review
Newman, David J.
Cragg, Gordon M.
Marine-Sourced Anti-Cancer and Cancer Pain Control Agents in Clinical and Late Preclinical Development (†)
title Marine-Sourced Anti-Cancer and Cancer Pain Control Agents in Clinical and Late Preclinical Development (†)
title_full Marine-Sourced Anti-Cancer and Cancer Pain Control Agents in Clinical and Late Preclinical Development (†)
title_fullStr Marine-Sourced Anti-Cancer and Cancer Pain Control Agents in Clinical and Late Preclinical Development (†)
title_full_unstemmed Marine-Sourced Anti-Cancer and Cancer Pain Control Agents in Clinical and Late Preclinical Development (†)
title_short Marine-Sourced Anti-Cancer and Cancer Pain Control Agents in Clinical and Late Preclinical Development (†)
title_sort marine-sourced anti-cancer and cancer pain control agents in clinical and late preclinical development (†)
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3917273/
https://www.ncbi.nlm.nih.gov/pubmed/24424355
http://dx.doi.org/10.3390/md12010255
work_keys_str_mv AT newmandavidj marinesourcedanticancerandcancerpaincontrolagentsinclinicalandlatepreclinicaldevelopment
AT cragggordonm marinesourcedanticancerandcancerpaincontrolagentsinclinicalandlatepreclinicaldevelopment